A study presented at the 2023 Society of Urologic Oncology Annual Meeting demonstrated the safety of durvalumab and tremelimumab-actl treatment followed by surgery in patients with advanced renal cell carcinoma. In the phase 1b study from 2016 to 2020, 25 mostly stage III patients underwent neoadjuvant therapy, nephrectomy, and adjuvant therapy. Most had radical nephrectomy for complex tumors. Despite no intraoperative complications, some had post-surgery issues. The findings support the safety of this treatment approach, with further tissue molecular analysis anticipated.
Reference: Broderick J. Durvalumab/Tremelimumab/Surgery Appears Safe in Renal Cell Carcinoma. CancerNetwork. Published November 30, 2023. Accessed December 20, 2023. https://www.cancernetwork.com/view/durvalumab-tremelimumab-surgery-appears-safe-in-renal-cell-carcinoma
